Shanghai Pharmaceuticals Financials
| 601607 Stock | 19.11 0.31 1.60% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Income | 10.2 B | 9.7 B |
|
|
Shanghai | Select Account or Indicator |
Understanding current and past Shanghai Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Shanghai Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Shanghai Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the presentation of Shanghai Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Shanghai Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Shanghai Pharmaceuticals' management manipulating its earnings.
Shanghai Pharmaceuticals Stock Summary
Shanghai Pharmaceuticals competes with Guangdong Jingyi, Guangzhou Restaurants, Jiaozuo Wanfang, Chongqing Shunbo, and Hefei Metalforming. Shanghai Pharmaceuticals is entity of China. It is traded as Stock on SHG exchange.Specialization | Health Care, Health Care Equipment & Services |
| Instrument | China Stock View All |
| Exchange | Shanghai Stock Exchange |
| ISIN | CNE000000C82 |
| Business Address | Shanghai Pharmaceutical Building, |
| Sector | Health Care Providers & Services |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.sphchina.com |
| Phone | 86 21 6373 0908 |
You should never invest in Shanghai Pharmaceuticals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Shanghai Stock, because this is throwing your money away. Analyzing the key information contained in Shanghai Pharmaceuticals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Shanghai Pharmaceuticals Key Financial Ratios
Shanghai Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from Shanghai Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of Shanghai Pharmaceuticals over time and compare it to other companies across industries.| Revenue | 275.25 B | ||||
| Gross Profit | 30.63 B | ||||
| EBITDA | 11.39 B | ||||
| Net Income | 4.55 B | ||||
| Total Asset | 221.21 B |
Shanghai Pharmaceuticals Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 149.2B | 163.4B | 198.1B | 212.0B | 221.2B | 232.3B | |
| Other Current Liab | 9.5B | 9.7B | 6.4B | 6.3B | 6.2B | 3.6B | |
| Retained Earnings | 26.9B | 30.6B | 34.6B | 33.8B | 36.5B | 38.4B | |
| Accounts Payable | 37.8B | 42.0B | 51.6B | 54.6B | 59.5B | 62.5B | |
| Cash | 22.3B | 22.4B | 27.4B | 30.5B | 35.7B | 37.5B | |
| Other Assets | 2.9B | 5.7B | 2.8B | 3.0B | 3.5B | 3.7B | |
| Long Term Debt | 1.2B | 7.2B | 6.3B | 5.8B | 8.3B | 8.7B | |
| Net Receivables | 52.7B | 58.1B | 66.8B | 72.9B | 79.1B | 83.1B | |
| Inventory | 24.1B | 27.1B | 34.5B | 36.6B | 38.9B | 40.9B | |
| Other Current Assets | 4.3B | 4.2B | 1.4B | 1.4B | 1.2B | 1.5B | |
| Total Liab | 94.4B | 104.4B | 120.1B | 131.6B | 137.5B | 144.3B | |
| Intangible Assets | 5.4B | 6.3B | 6.6B | 6.4B | 5.8B | 3.2B | |
| Other Liab | 2.1B | 2.7B | 3.6B | 4.0B | 4.5B | 4.8B | |
| Good Will | 11.3B | 11.2B | 11.3B | 11.4B | 11.1B | 7.6B | |
| Net Tangible Assets | 23.6B | 26.9B | 28.8B | 32.1B | 36.9B | 28.6B | |
| Short Long Term Debt | 20.1B | 22.5B | 27.8B | 35.6B | 38.1B | 23.1B | |
| Total Current Assets | 107.6B | 116.5B | 149.5B | 162.4B | 171.8B | 119.2B | |
| Net Invested Capital | 66.7B | 79.0B | 101.1B | 109.9B | 118.1B | 91.8B | |
| Net Working Capital | 19.4B | 24.7B | 38.8B | 40.1B | 45.8B | 32.4B |
Shanghai Pharmaceuticals Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Expense | 1.4B | 1.5B | 1.7B | 1.7B | 1.9B | 1.9B | |
| Total Revenue | 191.9B | 215.8B | 232.0B | 260.3B | 275.3B | 289.0B | |
| Operating Income | 8.1B | 7.9B | 8.8B | 9.6B | 9.7B | 10.2B | |
| Cost Of Revenue | 164.5B | 187.3B | 201.5B | 229.0B | 244.6B | 256.9B | |
| Income Before Tax | 7.2B | 8.1B | 8.8B | 7.1B | 8.0B | 8.4B | |
| Net Income | 4.5B | 5.1B | 5.6B | 3.8B | 4.6B | 2.3B | |
| Income Tax Expense | 1.4B | 1.6B | 1.9B | 1.8B | 2.1B | 2.2B | |
| Minority Interest | 9.4B | (1.2B) | (1.4B) | (1.4B) | (1.3B) | (1.3B) | |
| Research Development | 1.7B | 2.0B | 2.1B | 2.2B | 2.4B | 1.2B | |
| Gross Profit | 27.4B | 28.5B | 30.5B | 31.3B | 30.6B | 26.5B | |
| Ebit | 5.4B | 7.1B | 7.3B | 7.5B | 8.6B | 6.6B | |
| Tax Provision | 1.6B | 1.9B | 1.8B | 1.9B | 2.1B | 1.7B | |
| Net Interest Income | (1.2B) | (1.3B) | (1.3B) | (1.3B) | (1.5B) | (1.6B) | |
| Interest Income | 288.3M | 338.2M | 438.3M | 461.8M | 522.4M | 343.9M | |
| Ebitda | 9.5B | 10.7B | 10.7B | 12.7B | 14.6B | 10.7B |
Shanghai Pharmaceuticals Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Shanghai Pharmaceuticals. It measures of how well Shanghai is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Shanghai Pharmaceuticals brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Shanghai had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Shanghai Pharmaceuticals has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Dividends Paid | 2.4B | 2.7B | 3.1B | 4.0B | 3.6B | 3.8B | |
| Capital Expenditures | 3.0B | 4.1B | 2.7B | 3.0B | 2.4B | 1.4B | |
| Net Income | 4.5B | 5.1B | 5.6B | 3.8B | 4.6B | 2.3B | |
| Change To Inventory | 932.6M | (3.2B) | (7.1B) | (2.3B) | (2.3B) | (2.4B) | |
| Investments | (808.2M) | (86.7M) | (12.5B) | (2.5B) | 416.0M | 436.8M | |
| Change In Cash | 3.9B | 561.1M | 4.4B | 3.0B | 4.4B | 2.3B | |
| Net Borrowings | 7.6B | 930.7M | 865.2M | 3.2B | 2.9B | 2.4B | |
| Depreciation | 2.1B | 2.0B | 2.2B | 2.2B | 2.4B | 1.8B | |
| Change To Netincome | 1.7B | 2.5B | 2.1B | 1.0B | 1.2B | 1.4B | |
| End Period Cash Flow | 19.6B | 20.1B | 24.5B | 27.5B | 31.9B | 22.1B | |
| Free Cash Flow | 3.8B | 942.6M | 2.1B | 2.3B | 3.4B | 2.4B | |
| Other Non Cash Items | 1.6B | 1.8B | 1.9B | 2.1B | 2.0B | 1.8B |
Shanghai Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Shanghai Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Shanghai Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Shanghai Pharmaceuticals competition to find correlations between indicators driving Shanghai Pharmaceuticals's intrinsic value. More Info.Shanghai Pharmaceuticals Holding is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.39 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Shanghai Pharmaceuticals Holding is roughly 2.56 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Shanghai Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Shanghai Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Shanghai Pharmaceuticals Systematic Risk
Shanghai Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Shanghai Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-one with a total number of output elements of fourty. The Beta measures systematic risk based on how returns on Shanghai Pharmaceuticals correlated with the market. If Beta is less than 0 Shanghai Pharmaceuticals generally moves in the opposite direction as compared to the market. If Shanghai Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Shanghai Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Shanghai Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Shanghai Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Shanghai Pharmaceuticals Holding Total Assets Over Time
Shanghai Pharmaceuticals March 30, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Shanghai Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Shanghai Pharmaceuticals Holding. We use our internally-developed statistical techniques to arrive at the intrinsic value of Shanghai Pharmaceuticals Holding based on widely used predictive technical indicators. In general, we focus on analyzing Shanghai Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Shanghai Pharmaceuticals's daily price indicators and compare them against related drivers.
| Information Ratio | (0.14) | |||
| Maximum Drawdown | 4.24 | |||
| Value At Risk | (1.64) | |||
| Potential Upside | 1.47 |
Complementary Tools for Shanghai Stock analysis
When running Shanghai Pharmaceuticals' price analysis, check to measure Shanghai Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Shanghai Pharmaceuticals is operating at the current time. Most of Shanghai Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Shanghai Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Shanghai Pharmaceuticals' price. Additionally, you may evaluate how the addition of Shanghai Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |